Methylation biomarkers can also provide prognostic information. For instance, the methylation status of the CDKN2A gene, which encodes the tumor suppressor protein p16, can be used to determine the aggressiveness of certain cancers. Patients with hypermethylation of this gene often have a poorer prognosis compared to those without such methylation patterns.
